GLPwatch
Comment on "Superior Cerebrovascular Outcomes with Tirzepatide Versus Semaglutide in Diabetic CABG Patients: A Global Network Study of Propensity-Matched Patients".
Cardiovasc Drugs Ther · 2026
Last updated 2026-08-01| Journal | Cardiovasc Drugs Ther, 2026 |
|---|---|
| Citations | 1 |
| Molecules | semaglutide, tirzepatide |
| Conditions studied | Type 2 Diabetes, Cardiovascular Risk Reduction |
Full record and abstract on PubMed 41240220 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.